Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million. In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 8.88% and total debt rose 294.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow SRRK
Scholar Rock Holding Corporation (SRRK) EV/Sales
As of 16 October 2026, Scholar Rock Holding Corporation (SRRK) trades at a EV/Sales of 104×. Over the past ten years it has ranged from −2.3× (July 2022) to 160× (August 2026); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 6.5× | (82.82%) |
| FY2021 | 37.6× | (50.73%) |
| FY2020 | 76.3× | 645.66% |
| FY2019 | 10.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 6.7× | (82.22%) |
| Dec 2021 | 37.6× | (30.86%) |
| Sep 2021 | 54.4× | 7.24% |
| Jun 2021 | 50.7× | (50.77%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| TVTX Travere Therapeutics, Inc. compare | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| SRRK Scholar Rock Holding Corporation | 104× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)